Abstract
The modern multimodality therapeutic approach to Wilms tumor (WT), combining surgery with radiotherapy and chemotherapy results in high cure rates even for high stage disease. However, the combination of radiotherapy and chemotherapy is associated with severe early and late complications such as neutropenic sepsis, growth retardation and secondary malignancies. Therefore, novel therapeutic strategies, which would decrease the treatment burden, are required. We studied the expression of erbB2 growth factor receptor in WT cells as well as its role as a tumor therapeutic target in an in vivo xenograft model of Wilms tumor. Paraffin embedded pathological samples from 14 different WT cases as well as xenografts derived thereof were immunostained with anti-erbB2 monoclonal antibody. The immunostaining was graded in comparison to a known positive control (breast cancer) and was scored by the intensity of staining (0 to +3) multiplied by the percentage of cells expressing the antigen. The expression of erbB2 in the human WT xenograft was verified also by fluorescence activated cell sorter analysis. In addition, nude mice bearing established subcutaneous human WT xenografts were treated with either 3 intraperitoneal injections of N29 an...Continue Reading
References
Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·I StancovskiM Sela
Dec 18, 1990·Biochemistry·R GoldmanY Yarden
May 12, 1989·Science·D J SlamonA Ullrich
Jun 15, 1988·Journal of the National Cancer Institute·N E BreslowG J D'Angio
Jun 1, 1997·Virchows Archiv : an International Journal of Pathology·N H ChowI J Su
Mar 22, 2000·International Journal of Radiation Oncology, Biology, Physics·A C PaulinoD H Hussey
Jul 18, 2000·International Journal of Cancer. Journal International Du Cancer·B SeligerR Kiessling
Dec 7, 2000·Journal of the National Cancer Institute·H I Scher
Apr 13, 2001·Seminars in Oncology·D Slamon, M Pegram
Dec 26, 2001·Cancer·M A GhanemG J van Steenbrugge
Aug 24, 2002·Archives of Disease in Childhood·K Pritchard-Jones
Sep 3, 2002·Cancer Cell·Jose Baselga
Sep 3, 2002·Cancer Cell·David B AgusMark X Sliwkowski
Oct 5, 2002·Cancer·Gemma GattaFranco Berrino
Mar 22, 2003·Experimental Cell Research·Thomas HolbroNancy E Hynes
Aug 28, 2003·Cancer Immunology, Immunotherapy : CII·Malcolm S Mitchell
Citations
Sep 21, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Christopher BlackmoreAru Narendran
Jan 7, 2011·PloS One·Kaitlyn F WhelanJehonathan H Pinthus
Sep 17, 2008·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Eduard FridmanYoran Mor
Aug 31, 2013·Journal of Pediatric Urology·Mohammad-Javad MohseniAbdol-Mohammad Kajbafzadeh
Feb 25, 2014·Journal of Pediatric Urology·Lijuan ZhangRongde Wu
Jan 8, 2016·Annual Review of Pharmacology and Toxicology·Gideon Gross, Zelig Eshhar
Sep 29, 2009·Cancer Genetics and Cytogenetics·Mohammad VaseiGuido Sauter
Sep 2, 2006·The Journal of Urology·E FridmanY Mor
Apr 26, 2005·Clinics in Laboratory Medicine·Joseph D Khoury
Oct 11, 2011·The American Journal of Pathology·Peter E ClarkRoy Zent
Aug 7, 2010·Molecular Oncology·Andrew S GoldsteinOwen N Witte
Aug 5, 2005·The Oncologist·Richard J Gilbertson
Jun 17, 2006·Cancer Research·Benjamin DekelGideon Rechavi